Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023)

Historic Current Deferred Revenue for Spyre Therapeutics (SYRE) over the last 5 years, with Q2 2023 value amounting to $930000.0.

  • Spyre Therapeutics' Current Deferred Revenue rose 21958.76% to $930000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $930000.0, marking a year-over-year increase of 21958.76%. This contributed to the annual value of $2.7 million for FY2022, which is 1428.57% up from last year.
  • Spyre Therapeutics' Current Deferred Revenue amounted to $930000.0 in Q2 2023, which was up 21958.76% from $302000.0 recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Current Deferred Revenue registered a high of $19.2 million during Q1 2021, and its lowest value of $291000.0 during Q2 2022.
  • Its 3-year average for Current Deferred Revenue is $3.9 million, with a median of $2.2 million in 2021.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 9473.78% in 2022, then surged by 21958.76% in 2023.
  • Quarter analysis of 3 years shows Spyre Therapeutics' Current Deferred Revenue stood at $2.4 million in 2021, then grew by 14.29% to $2.7 million in 2022, then crashed by 65.5% to $930000.0 in 2023.
  • Its Current Deferred Revenue was $930000.0 in Q2 2023, compared to $302000.0 in Q1 2023 and $2.7 million in Q4 2022.